Office of Technology Transfer – University of Michigan

Functionally Blocking JAML Antibodies for the Treatment of Inflammatory Diseases

Technology #9999

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Categories
Researchers
Dr. Charles Parkos
Managed By
Robin Rasor
Managing Director of Licensing (734) 615-8433
Patent Protection

Nationalized PCT (United States)

Patent or Other Protection

Nationalized PCT (Foreign EP)

Patent or Other Protection

Functionally Blocking JAML Antibodies for the Treatment of Inflammatory Diseases

Application

Functionally blocking anti-human junctional adhesion molecule-like (JAML) antibodies for the treatment of inflammatory diseases, such as inflammatory bowel disease, rheumatoid arthritis, and skin or eye inflammatory diseases.

Key Benefits

Binds with higher affinity and specificity than currently available JAM antibodies based on comparative analyses.

Market Summary

Approximately 1.4 million individuals in the US and 2.2 million individuals in Europe have inflammatory bowel disease, which includes both Crohn’s disease and ulcerative colitis. There is currently no cure for inflammatory bowel disease and existing therapies must be taken for the remainder of the patient’s life. Examples of available therapeutics include corticosteroids, immunosuppressants, and monoclonal antibodies. Unfortunately, about 50 percent of patients do not benefit from these treatments, indicating a considerable unmet need for new, more effective therapies.

Technical Summary

Junctional adhesion molecules (JAMs) are a family of glycoproteins important in the control of vascular permeability and leukocyte transmigration across endothelial-cell surfaces. JAMs play a vital role in epithelial inflammation by regulating leukocyte transmigration and barrier function. Binding of JAML to its ligand Coxsackie and adenovirus receptor (CAR) provides T-cell co-stimulation leading to cellular proliferation and cytokine and growth factor production in the skin. Several monoclonal Abs have been produced that specifically bind JAML but not other JAMs. However, no antibodies have been produced that potently inhibit JAML-CAR binding. According to comparative analyses, these JAML antibodies bind with much higher affinity and specificity than currently available JAM antibodies and inhibit JAM-L mediated effects on CAR function.

Developmental Stage

Antibody binds JAM with great affinity and completely inhibits its function both in vitro and in vivo.

Patent Information

App Type   Country    Serial No.   File Date   Expire Date

Nationalized PCT  United States   14/238,556   Aug 10, 2012  Aug 10, 2032

Nationalized PCT  Foreign EP   12824085.0   Aug 10, 2012   Aug 10, 2032

Inventor(s) Charles Parkos; Dominique Weber;